dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Wieduwilt, Matthew |
dc.contributor.author | stock, wendy |
dc.contributor.author | Advani, Anjali |
dc.contributor.author | Luger, Selina |
dc.contributor.author | Larson, Richard |
dc.contributor.author | Tallman, Martin |
dc.contributor.author | Barba Suñol, Pere |
dc.date.accessioned | 2022-06-30T06:33:58Z |
dc.date.available | 2022-06-30T06:33:58Z |
dc.date.issued | 2021-07 |
dc.identifier.citation | Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, et al. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALG. Leukemia. 2021 Jul;35(7):2076–2085. |
dc.identifier.issn | 1476-5551 |
dc.identifier.uri | https://hdl.handle.net/11351/7765 |
dc.description | Leucèmia limfocítica aguda; Quimioteràpia |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Leukemia;35(7) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Leucèmia limfoblàstica - Quimioteràpia |
dc.subject | Medicaments antineoplàstics - Ús terapèutic |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Agents |
dc.subject.mesh | Disease-Free Survival |
dc.title | Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41375-021-01213-5 |
dc.subject.decs | leucemia-linfoma linfoblástico de células precursoras |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | antineoplásicos |
dc.subject.decs | supervivencia sin enfermedad |
dc.relation.publishversion | https://doi.org/10.1038/s41375-021-01213-5 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Wieduwilt MJ] University of California, San Diego Medical Center, La Jolla, CA, USA. [Stock W, Larson RA] University of Chicago Medicine, Chicago, IL, USA. [Advani A] Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA. [Luger S] Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA, USA. [Tallman M] Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [Barba P] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 33785862 |
dc.identifier.wos | 000635036100001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |